Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 3Small Cell Lung Carcinoma 2Meningioma 2Medulloblastoma 2Lung Neoplasms 2Breast Neoplasms 2Vipoma 1Somatostatinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pituitary Neoplasms 1Pinealoma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Insulinoma 1Hodgkin Disease 1Growth Hormone-Secreting Pituitary Adenoma 1Glucagonoma 1Gliosarcoma 1Glioma, Subependymal 1

Interventions

Cyclophosphamide 56Etoposide 40Filgrastim 37Carboplatin 34Vincristine 30Doxorubicin 30Melphalan 27Topotecan 25Isotretinoin 24Peripheral Blood Stem Cell Transplantation 23Granulocyte Colony-Stimulating Factor 22Cisplatin 21Irinotecan 20sargramostim 18Temozolomide 17humanized 3F8 anti-GD2 monoclonal antibody 15Radiotherapy 153-Iodobenzylguanidine 13Granulocyte-Macrophage Colony-Stimulating Factor 11Busulfan 11dinutuximab 10Interleukin-2 9aldesleukin 8Thiotepa 8Ifosfamide 8etoposide phosphate 7Mesna 7Vorinostat 6Stem Cell Transplantation 6Polymerase Chain Reaction 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neuroblastoma × 90Y-octreotide, DOTA-Tyr(3)- × Clear all
NCT03273712 2023-02-09

Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

University of Iowa

Phase 2 Completed
39 enrolled 9 charts
CNSEndocrineNET

Medulloblastoma, Meningioma, Neuroblastoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡